BEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in October 2026.

Upcoming Investor Conference:

Chardan 10th Annual Healthcare Conference:
Date: Tuesday, October 20, 2026
Fireside Chat: 9:45 AM ET
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: New York, NY

A live webcast of the Chardan fireside chat can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcasts will be archived for at least 30 days following the presentation.

Upcoming Scientific Conferences:

Eyecelerator @ AAO 2026: October 8, 2026
New Orleans, Louisiana

  • Company Presentation: Ocular Therapeutix: Redefining the Retina Experience
    Session: Retina-Biologics, Diagnostics, & AI Showcase
    Session Date/Time: Thursday, October 8, 2026, 1:43 – 1:48 PM CT
    Presenter: Peter K. Kaiser, MD, Chief Development Officer
  • Panel Discussion: The Odyssey: Industry Heroes Seeking Safe Passages and Happy Returns
    Panel Date/Time: Thursday, October 8, 2026, 3:45 – 4:30 PM CT
    Panelist: Pravin U. Dugel, MD, Executive Chairman, President and CEO

Innovate Retina: October 8, 2026
New Orleans, Louisiana

  • Presentation: Sustained Hydrogel Delivery in Neovascular AMD: Topline Outcomes from the Phase 3 SOL-1 Trial with Hydrogel-Formulated Axpaxli
    Session: Ocular Gene Therapies & Advanced Therapeutics
    Session Date/Time: Thursday, October 8, 2026, 5:35 – 5:39 PM CT
    Presenter: Arshad M. Khanani, MD, MA, FASRS
  • Panel Discussion
    Session: Industry Insights & Advanced Therapeutics
    Panel Date/Time: Thursday, October 8, 2026, 6:45 – 7:15 PM CT
    Panelist: Peter K. Kaiser, MD, Chief Development Officer

American Academy of Ophthalmology Retina Subspeciality Day: October 9 – 10, 2026
New Orleans, Louisiana

  • Presentation: Phase 3 Trial of OTX-TKI (SOL-1) for Wet AMD
    Session: Section X: Clinical Trial Updates, Part I
    Presentation Date/Time: Friday, October 9, 2026, 4:35 – 4:40 PM CT
    Presenter: Darius M. Moshfeghi, MD, FASRS

American Academy of Ophthalmology: October 9-12, 2026
New Orleans, Louisiana

  • Presentation: Redefining the Management of nAMD: The Impact of Durability and Sustained Disease Control
    Session: Industry Showcase
    Session Date/Time: Saturday, October 10, 2026, 11:30 AM – 12:30 PM CT
    Faculty: Arshad M. Khanani, MD, MA, FASRS; Mark R. Barakat, MD, FASRS; Dilsher S. Dhoot, MD, FASRS
  • Presentation: SOL-1 Phase 3 Superiority Trial Evaluating Intravitreal Axitinib Hydrogel (OTX-TKI) in nAMD
    Presentation Date/Time: Monday, October 12, 2026, 9:00 – 9:07 AM CT
    Presenter: Mark R. Barakat, MD, FASRS

Exact medical conference presentation times may be subject to change.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized multiple atherosclerotic cardiovascular disease (ASCVD) pathogenic drivers of local plaque inflammation, thrombosis, and systemic inflammation

Robust and sustained NEK7 degradation observed across 5 mg, 20 mg, and 40 mg once-daily dose levels, with similar biomarker reductions at all three doses

HMGB1, calprotectin, S100A12, and SAA, damage-associated molecular patterns (DAMPs) linked to atherosclerotic plaque progression and instability, and IL-1β, all established key pathogenic drivers of ASCVD, were reduced to levels comparable to normal physiological levels seen in the healthy volunteer population of Phase 1 study

MRT-8102 was safe and well tolerated over four weeks of dosing and four weeks of follow-up, with no serious adverse events, treatment-emergent adverse event rates comparable to placebo, and no evidence of increased infection risk

Phase 2 trials planned across coronary artery disease (GFORCE-2), gout (GEMINI-1), and moderate to severe hidradenitis suppurativa (GALAXY-1)

Company to host conference call and webcast today, Oct. 1, at 8:00 a.m. ET

BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced positive data from GFORCE-1, a Phase 1 study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NEK7/NLRP3 pathway.

“The GFORCE-1 data are highly encouraging and show that MRT-8102 does precisely what we designed it to do: potently and selectively degrade NEK7 and reduce levels of upstream and downstream drivers of residual plaque inflammation and thrombotic risk, and it does so with a differentiated and favorable safety profile,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. “We are particularly excited about our translational approach, including our unique and broad analysis of the NEK7/NLRP3 upstream pathway, that has allowed us to gain unprecedented insights into how inhibition of the pathway through NEK7 degradation leads to normalization of many of the most important drivers of atherosclerotic plaque formation, progression, and rupture. To that end, we observed compelling reductions of HMGB1, calprotectin, S100A12, SAA, and IL-1β. These DAMPs and cytokines are linked to pathogenic biology within atherosclerotic plaques and vessel walls, and they have been identified as independent risk factors of much greater significance than some of the systemic inflammatory markers evaluated in other studies. We have also seen intriguing correlation of these markers with NLRP3 risk alleles, opening up opportunities for a precision medicine approach. The GFORCE-1 study results, alongside a body of genetic, biological, and clinical data, reinforce our rationale for degrading NEK7 to simultaneously dampen multiple key ASCVD disease drivers that can lead to atherosclerosis, plaque progression, and thrombogenesis. We believe targeting NEK7 at the top of the NLRP3 signaling cascade has the potential to provide a degree of clinical impact across NEK7/NLRP3-driven diseases not achievable by targeting individual downstream cytokines.”

Filip Janku, M.D., Ph.D., Chief Medical Officer of Monte Rosa Therapeutics, commented, “We believe our results represent the most comprehensive translational data set reported to date for the NEK7/NLRP3 pathway. GFORCE-1 was designed to provide a broad view of the pharmacodynamic activity and safety of MRT-8102, and the profile we observed further bolsters our enthusiasm for continued development in cardiovascular disease and other indications. With dose selection now informed by these data, we plan to initiate GFORCE-2, a focused Phase 2b study in patients with coronary artery disease, in the first half of 2027. In GFORCE-2, our goal is to connect imaging-based coronary artery plaque assessment, such as fat attenuation index (FAI), with NLRP3 genetics and molecular drivers of local disease pathogenesis and systemic inflammation to inform the design of an innovative and efficient Phase 3 study focused on the most disease-modifiable patient population. We also expect to initiate GEMINI-1, a Phase 2 study in gout, in Q4 2026 or Q1 2027, and GALAXY-1, a Phase 2 study in moderate to severe hidradenitis suppurativa, in the first half of 2027, representing additional substantial opportunities associated with this pathway.”

GFORCE-1 (clinicaltrials.gov identifier NCT07119125) enrolled 108 obese subjects with elevated CVD risk, randomized to MRT-8102 at once-daily doses of 5 mg, 20 mg, or 40 mg, or to placebo. The GFORCE-1 study followed best-in-class data from the single ascending dose (SAD) and multiple ascending dose (MAD) cohorts in healthy volunteers, and those data were previously reported. The GFORCE-1 study evaluated safety and tolerability, along with multiple pharmacodynamic markers, over a four-week treatment regimen, followed by four weeks of safety follow-up. Multiple dose levels were explored to support dose selection for further development across various NLRP3-driven diseases, including ASCVD, gout, and hidradenitis suppurativa.

Summary of GFORCE-1 Results

  • GFORCE-1 enrolled 108 obese subjects with elevated CVD risk, randomized to MRT-8102 at 5 mg, 20 mg, or 40 mg once daily, or to placebo, for 4 weeks of dosing and 4 weeks of follow-up safety evaluation.
  • MRT-8102 achieved robust and sustained NEK7 degradation, with a median reduction of approximately 80 to 90% observed across all three dose levels.
  • Both local drivers of plaque growth and progression and systemic inflammatory biomarkers were substantially reduced following MRT-8102 administration at all three dose levels to levels comparable with baseline values from Phase 1 healthy volunteers.
  • Median values of calprotectin, S100A12, and SAA, which are critical drivers of ASCVD progression, were lowered by 56%, 46%, and 51%, respectively.
  • Median values of HMGB1 and IL-1β were elevated at baseline and decreased toward healthy volunteer levels following treatment among subjects with elevated levels. Median reductions were 40% and 37%, respectively, in subjects with levels in the top quartile.
  • The thrombogenic factor fibrinogen was reduced by a median of 28% to levels consistent with those in healthy volunteers.
  • IL-6 and hsCRP, biomarkers of systemic inflammation, were reduced by a median of 54% and 85%, respectively. All three doses of MRT-8102 resulted in rapid and sustained reductions in hsCRP to levels comparable to baseline in healthy volunteers from the healthy volunteer cohorts.
  • MRT-8102 administration reduced median lipoprotein(a) by 24%, comparable to PCSK9 inhibitors. Unlike IL-6(R) blockade, MRT-8102 treatment did not increase LDL-C or triglyceride levels.
  • Significant increases in baseline biomarker levels were identified in carriers of NLRP3 risk alleles (approximately 30% of the GFORCE-1 population), particularly for DAMPs and IL-1β, suggesting a higher-risk, genetically enrichable population for potential future development.
  • MRT-8102 was well tolerated over four weeks of dosing and four weeks of follow-up. No serious adverse events (SAEs) were reported. Rates of treatment-emergent adverse events (TEAEs) were similar between MRT-8102 and placebo, occurring in 33% of MRT-8102 participants and 30% of placebo participants, with no evidence of increased infection risk.

Phase 2 Program for MRT-8102

Monte Rosa expects to initiate multiple Phase 2 studies of MRT-8102 in indications with high unmet need and strong biologic rationale for targeting the NEK7/NLRP3 pathway:

  • GFORCE-2, a focused Phase 2b study of MRT-8102 in patients with stable coronary artery disease and residual inflammation, is expected to initiate in H1 2027. The study design, pending regulatory feedback, will evaluate changes in local pathogenic drivers of ASCVD, systemic biomarkers, and cardiovascular imaging over a six-month dosing period to specifically observe modulation of plaque biology, as well as changes in inflammatory, thrombogenic, and lipid mediators of disease. The Company is working to complete long-term preclinical toxicology studies to support this 6-month study.
  • GEMINI-1, a Phase 2 study of MRT-8102 in patients with gout, is expected to initiate in Q4 2026 or Q1 2027. The study will investigate prevention of flare recurrence following management of acute flares with MRT-8102. Initial data are expected in H2 2027.
  • GALAXY-1, a Phase 2 study of MRT-8102 in patients with moderate to severe hidradenitis suppurativa, is expected to initiate in H1 2027.

Investor Conference Call

Monte Rosa will host a conference call and webcast presentation today, October 1, 2026, at 8:00 a.m. ET. A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com. Registration for the conference call is available at the following link. An archived version of the webcast will be made available for 30 days following the presentation.

About MRT-8102

MRT-8102 is a potent, highly selective, and orally bioavailable investigational molecular glue degrader (MGD) that targets NEK7 for the treatment of inflammatory diseases linked to NLRP3 and IL-1 dysregulation. NEK7 has been shown to be required for NLRP3 inflammasome assembly, activation, and IL-1β release both in vitro and in vivo. NLRP3 inflammasome activation causes pyroptotic cell death, leading to the release of IL-1α/β, IL-18, and DAMPs such as HMGB1, calprotectin, S100A12, and SAA. IL-1β and IL-18 are highly inflammatory cytokines, and DAMPs further stimulate NLRP3 activity while promoting NLRP3-independent cytokine and chemokine production in neighboring cells. Together, DAMPs and IL-1 are responsible for the majority of the local inflammation and tissue changes characteristic of ASCVD, gout, hidradenitis suppurativa, and other indications. The NEK7/NLRP3 inflammasome plays a multifaceted role in plaque biology, contributing to plaque formation, plaque growth, vessel wall alterations, and thrombosis.

About Monte Rosa

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology, and neurology. For more information, visit www.monterosatx.com.

Forward-Looking Statements

This communication includes express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements contained herein include, but are not limited to, statements about our ability to grow our product pipeline, our ability to successfully complete research and further development and commercialization of our drug candidates in current or future indications, including the timing and results of our clinical trials and our ability to conduct and complete clinical trials, statements regarding our progress and speed of development of only-in-class and first-in-class molecular glue degrader therapeutics, statements around the Company’s QuEEN™ discovery engine and the broad potential applications of the platform and the Company’s ability to create long-term value through focused pipeline execution and strategic collaborations, statements about the advancement and timeline of our preclinical and clinical programs, pipeline and the various products therein, statements regarding the positive Phase 1 data of MRT-8102 from the GFORCE-1 study, including the safety, tolerability, target engagement, and other results observed, statements regarding the potential of MRT-8102 to normalize local and systemic pathologic drivers of ASCVD and to address NLRP3/IL-1-driven inflammatory diseases, our expectations regarding the potential of targeting NEK7 at the top of the NLRP3 inflammasome signaling cascade to provide differentiated clinical impact across NLRP3-driven diseases, including compared with targeting individual downstream cytokines, statements regarding the planned initiation of GFORCE-2, a Phase 2b study of MRT-8102 in patients with stable coronary artery disease and residual inflammation, including the expected timing, study design, regulatory feedback regarding the study design, use of coronary artery imaging, NLRP3 genetics and biomarkers to identify a disease-modifiable patient population and inform the design of a potential Phase 3 study, and the completion of long-term preclinical toxicology studies to support GFORCE-2, statements regarding the planned initiation of GEMINI-1, a Phase 2 study of MRT-8102 in patients with gout, including the expected timing, study design and objective of evaluating prevention of flare recurrence, and the expected timing of initial data, statements regarding the planned initiation of GALAXY-1, a Phase 2 study of MRT-8102 in patients with moderate to severe hidradenitis suppurativa, including the expected timing, statements regarding dose selection informed by GFORCE-1 data for further development across various NLRP3-driven diseases, statements regarding a genetically enrichable higher-risk population identified through NLRP3 risk alleles for potential future development, statements regarding opportunities for MRT-8102 in inflammatory diseases and statements around our expectations of success for our programs, among others. By their nature, these statements are subject to numerous risks and uncertainties, including those risks and uncertainties set forth in our most recent Annual Report on Form 10-K for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission on March 17, 2026, and any subsequent filings, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements, as well as the risk that outcomes of preclinical studies may not be predictive of clinical trial results and the risk that initial or interim results from a clinical trial may not be predictive of the final results of the trial or the results of future trials. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations, or otherwise, except as required by applicable law. Certain information contained in these materials and any statements made orally during any presentation of these materials that relate to the materials or are based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party studies, publications, surveys and other data to be reliable as of the date of these materials, we have not independently verified, and make no representations as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of our internal estimates or research and no reliance should be made on any information or statements made in these materials relating to or based on such internal estimates and research.

Investors
Andrew Funderburk
ir@monterosatx.com

Media
Cory Tromblee, Scient PR
media@monterosatx.com

  • Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader program
  • Company to focus resources on wholly owned pipeline, including a Selective EP300 degrader, a novel, oral immunology and inflammation program, a Selective CBP degrader and induced proximity platform
  • Pipeline prioritization and organizational changes expected to extend cash runway into the second half of 2029, including an approximately 40% workforce reduction

WATERTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a biotechnology company pioneering a new class of medicines that treat serious diseases, today announced that, following a review of clinical data from the Phase 1 dose escalation trial of FHD-909 (LY4050784), Foghorn and Lilly have decided not to advance the program into the clinical development expansion phase. The Collaboration also will not be advancing the Selective SMARCA2 degrader program, and the companies do not anticipate further collaboration activities. As a result, Foghorn is prioritizing resources toward its proprietary portfolio programs with the greatest potential to address significant patient needs and create long-term value.

“While we are disappointed with the clinical results, we and Lilly developed a drug in FHD-909 that selectively hits the SMARCA2 target with a favorable safety profile at exposures that exceeded our preclinical targets. Unfortunately, the biology of the SMARCA2/4 synthetic lethality relationship has not translated into the level of efficacy required to further advance the program,” said Adrian Gottschalk, President and Chief Executive Officer of Foghorn Therapeutics. “We built Foghorn based on a demonstrated capability in designing drugs for challenging molecular targets, and we have leveraged this capability to build a proprietary pipeline. Today, we are committed to focusing our financial and developmental resources to advance these programs toward the clinic.”

“Foghorn is reducing its workforce by approximately 40% and further aligning its operating structure resulting in cash to fund Foghorn’s priority programs into the second half of 2029. These proprietary programs include our EP300 degrader program, our novel, oral immunology and inflammation program, our CBP degrader program, and our induced proximity platform.

Mr. Gottschalk continued, “I would like to thank our partner Lilly for their support, as well as the patients, caregivers, investigators, study site staff, and all others who participated in and contributed to the FHD-909 clinical trial.”

About FHD-909
FHD-909 (LY4050784) is a potent, first-in-class, allosteric, and orally available small molecule that selectively inhibits the ATPase activity of SMARCA2 (BRM) over its closely related paralog SMARCA4 (BRG1), two proteins that are the catalytic engines across all forms of the BAF complex, one of the key regulators of the chromatin regulatory system.

About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing product candidates in oncology and in immunology & inflammation. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.

Forward-Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include statements regarding the Company’s preclinical programs, including its selective CBP and selective EP300 degrader programs, selective ARID1B degrader program, its induced proximity efforts, its novel oral small molecule in immunology and inflammation, and other preclinical product candidates, expected cash runway, expected timing of regulatory filings, and research efforts and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made.

Contact:
Karin Hellsvik, Foghorn Therapeutics Inc.
khellsvik@foghorntx.com

–   RECEPTIVE-HS1 Phase 2 clinical trial in patients with moderate to severe hidradenitis suppurativa (HS) expected to initiate in 2026; data from the 16-week treatment period expected in the first half of 2028   –

–   HS is the second Phase 2 indication for SL-325 and expands development beyond IBD   –

–   Announces appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development; Dr. Ravichandran to lead the HS clinical development program   –

–   Cash runway guidance remains unchanged, with existing cash expected to fund operations into 2029   – 

AUSTIN, TX and DURHAM, NC, Oct. 01, 2026 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced its plans to evaluate SL-325 in a Phase 2 clinical trial in patients with moderate to severe hidradenitis suppurativa (HS).

“We are excited to see the recent clinical validation of the TL1A/DR3 axis in patients with moderate to severe HS. We expect, by targeting DR3 instead of TL1A, SL-325 may provide potentially best-in-mechanism efficacy in indications where the TL1A/DR3 axis is proven active. Only a few biologic therapies are available to patients with moderate to severe HS, and the emerging data support the potential for TL1A/DR3 blockade to provide best-in-disease efficacy,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck. “We are also very pleased to welcome Dr. Shoba Ravichandran to the team as Senior Vice President, Clinical Development. Dr. Ravichandran’s deep clinical development experience, including leading Cosentyx to approval in HS, will be important in driving toward Phase 2b data for the RECEPTIVE-HS1 study in the first half of 2028.”

RECEPTIVE-HS1 Phase 2 Trial of SL-325 in Hidradenitis Suppurativa

The RECEPTIVE-HS1 study is designed as a randomized, double-blind, placebo-controlled Phase 2 clinical trial to evaluate the efficacy and safety of two dose levels of SL-325 versus placebo in patients with moderate to severe HS. The trial will include a 16-week placebo-controlled treatment period followed by an extension period with SL-325 through Week 52.

  • RECEPTIVE-HS1 is expected to enroll approximately 150 patients, randomized 1:1:1 to receive low dose SL-325, high dose SL-325, or placebo.
  • The trial is expected to enroll patients with moderate to severe HS who have five or more abscesses and inflammatory nodules (AN count), no more than 20 draining tunnels, and Hurley stage II or III disease.
  • The primary endpoint is the proportion of patients achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16, defined as at least a 50% reduction in AN count, with no increase in abscess or draining tunnel counts relative to baseline.
  • Key secondary endpoints include the proportion of patients achieving HiSCR75 at Week 16, as well as safety and tolerability.
  • Patients randomized to the placebo arm for the initial 16-week treatment period may elect to receive SL-325 during the extension period.
  • In addition to efficacy, the RECEPTIVE-HS1 study will further characterize the pharmacokinetics and immunogenicity of SL-325 in patients with HS.
  • IND submission is expected in October 2026.
  • Week 16 data for the primary and secondary endpoints are expected to be disclosed in the first half of 2028.

Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development

Dr. Shoba Ravichandran joins Shattuck Labs as Senior Vice President, Clinical Development, and brings more than 20 years of drug development experience, including five successful major U.S. and global regulatory filings. She spent over a decade at Novartis, and in her most recent role as Senior Global Program Clinical Head, led the global approval of Cosentyx in HS and Phase 3 start-up activities for remibrutinib in HS.

Dr. Ravichandran commented, “I am delighted to join the Shattuck team and lead development of SL-325 in HS, a disease with very high unmet need and one where I believe SL-325 can be a differentiated and exciting future treatment option for patients.”

About Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by recurrent painful nodules, abscesses and draining tunnels. The pathogenesis of HS is multifactorial and involves dysregulation of both innate and adaptive immune responses, including Th1- and Th17-associated inflammatory pathways. HS is estimated to affect approximately 1% of the global population, although prevalence estimates vary by geography and methodology. The disease can cause chronic pain, irreversible tissue damage and scarring, and can substantially impair quality of life. DR3 was shown to be highly expressed in HS lesions, and in greater abundance than TL1A. Importantly, the extent of DR3 expression was shown to correlate with the expression of other validated pathways in HS, including IL-17A, IL-17F, TNFα and IL-1R1, highlighting the therapeutic potential of targeting DR3.

About SL-325
SL-325 is a potentially first-in-class Death Receptor 3 (DR3) blocking antibody designed to achieve a complete and durable blockade of the clinically validated DR3/TL1A pathway. Shattuck’s preclinical studies demonstrated high affinity binding and superior activity over TL1A antibodies, and provided a data-driven rationale for targeting the TNF receptor, DR3, versus its ligand, TL1A. SL-325 is a fully Fc-silenced, fully human immunoglobulin G monoclonal antibody. In a Phase 1 clinical trial, SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, no evidence of residual DR3 agonism, and provided durable blockade of TL1A binding to DR3 at low doses. SL-325 is being evaluated in a Phase 2 clinical trial in patients with Crohn’s disease, with data expected in the first half of 2028.

About Shattuck Labs, Inc.
Shattuck Labs, Inc. is a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Shattuck’s expectations regarding: plans for its preclinical studies, clinical trials and research and development programs, particularly with respect to SL-325; the anticipated timing of initiation and expected enrollment of a Phase 2 clinical trial of SL-325 in patients with Crohn’s disease; the anticipated timing of initiation and expected enrollment of a Phase 2 clinical trial of SL-325 in patients with hidradenitis suppurativa; the clinical benefit, safety and tolerability of SL-325; anticipated development of additional preclinical pipeline candidates; the anticipated timing of initiation of a Phase 1 clinical trial of SL-846; the clinical benefit, safety and tolerability of SL-846; the anticipated release of data from SL-846; the potential clinical significance of clinical and preclinical data and expectations regarding the time period over which the Company’s capital resources will be sufficient to fund its anticipated operations. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan,” “anticipate” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to it on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Shattuck’s filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond its control and subject to change. Actual results or outcomes, or the timing of actual results or outcomes, could be materially different. Risks and uncertainties include: global macroeconomic conditions and related volatility; expectations regarding the initiation, progress, and expected results of the Company’s preclinical studies, clinical trials and research and development programs, including the timing and costs thereof; the Company’s ability to enroll patients in its clinical trials; the unpredictable relationship between preclinical study results and clinical study results; the Company’s ability to advance product candidates into, and successfully complete, nonclinical studies and clinical trials; the timing or likelihood of regulatory filings and approvals; the implementation of the Company’s business model, strategic plans for its business and product candidates; the scope of protection the Company is able to establish and maintain for intellectual property rights covering its technology; liquidity and capital resources, including the time period over which current capital resources are expected to the fund the Company’s operations; and other risks and uncertainties identified in Shattuck’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent filings with the SEC. Shattuck claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. The Company expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

Investor & Media Contact:
Andrew R. Neill
Chief Financial Officer
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com 

CHICAGO, Oct. 01, 2026 (GLOBE NEWSWIRE) — TransUnion (NYSE: TRU) will publish its financial results for the third quarter ended September 30, 2026, in a press release to be issued at approximately 6:00 a.m. Central Time (CT) on Tuesday, October 27, 2026.   The company will hold a conference call on the same day at 8:30 a.m. (CT) to discuss its financial results. The press release and a live webcast of the earnings conference call will be available on the TransUnion Investor Relations website at http://www.transunion.com/tru.

About TransUnion (NYSE: TRU)

TransUnion is a global information and insights company with over 13,000 associates operating in more than 30 countries. We make trust possible by ensuring each person is reliably represented in the marketplace. We do this with a Tru™ picture of each person: an actionable view of consumers, stewarded with care. Through our acquisitions and technology investments we have developed innovative solutions that extend beyond our strong foundation in core credit into areas such as marketing, fraud, risk and advanced analytics. As a result, consumers and businesses can transact with confidence and achieve great things. We call this Information for Good® — and it leads to economic opportunity, great experiences and personal empowerment for millions of people around the world.

http://www.transunion.com/business

E-mail  Gregory.Bardi@transunion.com
   
Telephone 312-985-2860

LONDON and ATLANTA , Oct. 01, 2026 (GLOBE NEWSWIRE) — The Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that customs brokerage Manifests Ireland has increased its annual customs declaration volumes from approximately 20,000 before Brexit in 2020 to 2 million today. Powered by the Descartes Thyme™ customs platform and a long-term collaboration, the Dublin-based company has successfully scaled its operations, adapted to major regulatory changes and maintained the high levels of accuracy, compliance and customer service on which its reputation is built.

“Growth creates opportunities, but it also places new demands on your business,” said Derek Dunne, Managing Director at Manifests Ireland. “As declaration volumes have grown and customs requirements have become more complex, automation has helped us work faster and with greater accuracy and visibility. Descartes Thyme gives us the confidence to scale while continuing to deliver the compliance and service our clients expect. Underpinning that is a long-standing relationship with Descartes built on trust and a genuine understanding of our business.”

Today, Descartes Thyme™ sits at the heart of Manifests Ireland’s operations, helping automate key processes, reduce manual intervention, minimise errors and improve team efficiency. The web-based platform integrates with Irish Revenue’s Automated Import System (AIS) and Automated Export System (AES), enabling customers to create, submit and track declarations securely through a single solution. Support for individual and bulk submissions helps businesses process growing declaration volumes efficiently and make better use of data already held within their operations. The broader suite also supports processes such as transit declarations, pre-boarding notifications and goods vehicle movements, helping customs brokers manage trade operations with greater accuracy and visibility while maintaining compliance and high levels of customer service.

Beyond technology, Manifests Ireland cites the strength of the collaboration and support provided by the Descartes team as a key factor in its long-term success. “Customs brokerage remains a people-driven business,” Dunne added. “What has always stood out is the continuity of the relationship. We work with people who understand our business, respond quickly when we need support and collaborate closely with us as regulations and requirements evolve. That trust has been invaluable throughout our growth journey.”

The close cooperation between the two organisations has included support through major customs modernisation initiatives and regulatory changes, including the implementation of systems such as AIS, AES and NCTS. During the period following Brexit, when customs declaration volumes increased dramatically, Descartes helped Manifests Ireland absorb unprecedented growth while maintaining operational efficiency, compliance and service continuity. Working together, the customs brokerage specialist has consistently embraced new requirements early, helping ensure smooth transitions and uninterrupted service for customers.

Manifests Ireland is now focused on the next stage of its business strategy. Having established a strong presence in Ireland and the UK, the company is actively exploring opportunities across mainland Europe.
“We are increasingly supporting customers with cross-border trade requirements beyond Ireland,” said Dunne. “As we expand into new markets, having a partner with global reach, proven technology and ongoing investment in compliance becomes even more important. Descartes gives us the confidence to grow knowing we have the infrastructure, expertise and support needed to serve customers across multiple jurisdictions.”

“Growing from approximately 20,000 to 2 million declarations per year is an impressive achievement and a testament to Manifests Ireland’s expertise and commitment to customer service,” said James Stafford, Divisional Director, LSP EMEA at Descartes. “For more than two decades, our teams have worked closely together to help the company adapt to changing customs requirements, improve operational efficiency and support international expansion across Europe.”

About Manifests Ireland

Manifests Ireland is a specialist customs brokerage focused exclusively on customs declarations. With more than 40 years of customs expertise, the company provides customs compliance and brokerage services for businesses trading across Ireland, the UK and international markets. By focusing solely on customs requirements, Manifests Ireland delivers best-in-class customs brokerage services that help customers navigate increasingly complex trade environments. Learn more about Manifests Ireland at www.manifests.ie.

About Descartes

Descartes powers more responsive, efficient, secure and sustainable international and domestic supply chains by uniting logistics-intensive businesses on its Global Logistics Network (GLN). Shippers, carriers, and logistics service providers connect and collaborate on the GLN leveraging technology, data and AI to manage last mile deliveries, domestic and international shipments, transportation rating and payment, global trade research, customs compliance and a variety of regulatory processes. Learn more about Descartes at www.descartes.com and connect with us on LinkedIn and X.

Global Media Contact
Andra Schaz
Tel.: +49 (0)170 631 15 52
Email: aschaz@descartes.com

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”) that relate to Descartes’ customs and regulatory compliance solution offerings and potential benefits derived therefrom; and other matters. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the factors and assumptions discussed in the section entitled, “Certain Factors That May Affect Future Results” in documents filed with the Securities and Exchange Commission, the Ontario Securities Commission and other securities regulatory authorities across Canada including Descartes’ most recently filed annual and interim management’s discussion and analysis which are available under Descartes’ profile through the EDGAR website at http://www.sec.gov or through the SEDAR+ website at http://www.sedarplus.com/. If any such risks actually occur, they could, among other consequences, materially adversely affect our business, financial condition or results of operations. In that case, the trading price of our common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. Except as required by applicable law, we do not undertake or accept any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Natural Gas Service Will Continue Without Interruption; No Customer Action Required

WILLIAMSVILLE, N.Y., Oct. 01, 2026 (GLOBE NEWSWIRE) — National Fuel Gas Company (“National Fuel” or the “Company”) (NYSE: NFG) today announced it has completed its previously announced acquisition of CenterPoint Energy’s Ohio natural gas utility business, Vectren Energy Delivery of Ohio, LLC. The transaction closed today, following the satisfaction of customary closing conditions.

The newly acquired utility, which will be renamed National Fuel Gas Distribution of Ohio, LLC, serves approximately 335,000 customers across 16 counties in the Dayton and greater Miami Valley region.

“This acquisition is an important milestone, representing a significant step forward in advancing the strategy of growing our regulated utility business,” David P. Bauer, President and Chief Executive Officer of National Fuel Gas Company, said. “With the addition of the Ohio service territory, we have significantly expanded our regulated footprint and strengthened the long-term foundation of the Company. We look forward to serving our new customers while maintaining our longstanding commitment to best-in-class safety, reliability and customer service.”

The acquisition adds meaningful regulated scale for National Fuel, doubling its utility rate base while expanding its operations into the neighboring state of Ohio, a jurisdiction that is both highly supportive of natural gas and maintains a constructive regulatory framework.  With this closing, the Company’s utility customer base grows to approximately 1.1 million customers. The transaction is an example of National Fuel’s disciplined approach to capital allocation and is expected to provide a platform for continued regulated investment opportunities, further balancing the Company’s business mix.

Information for Customers

  • Natural gas service will continue uninterrupted.
  • No action is required at this time.
  • Existing billing cycles and payment methods will remain unchanged.
  • Current online account access will continue in the immediate future.
  • Customers will receive advance notice of any future service-related changes.

“We are excited to welcome our new customers in Ohio to National Fuel,” said Michael D. Colpoys, President of National Fuel Gas Distribution Corporation. “For 125 years, National Fuel has been focused on delivering natural gas safely, reliably and affordably. Our message to customers is simple: your service will continue uninterrupted, and our focus is on providing the highest quality service from day one. We look forward to earning the trust of customers across the greater Dayton and Miami Valley region and serving them with the same dedication that has defined National Fuel for generations.”

National Fuel also welcomes approximately 200 employees joining the Company as part of the acquisition.

“The employees joining National Fuel today are the same dedicated professionals that customers have come to know and trust,” Colpoys said. “We look forward to building on the strong operational foundation they have established. Their experience, expertise and deep connection to the communities we serve will be an important part of our success in Ohio.”

National Fuel also reaffirms its commitment to the Ohio communities it now serves. The Company plans to be an active corporate citizen through support of local organizations, community initiatives and employee volunteerism programs.

About National Fuel

National Fuel is an integrated energy company reporting financial results for three operating segments: Integrated Upstream and Gathering, Pipeline and Storage, and Utility. Additional information about National Fuel is available at www.nationalfuel.com.

Certain statements contained herein, including statements identified by the use of the words “anticipates,” “estimates,” “expects,” “forecasts,” “intends,” “plans,” “predicts,” “projects,” “believes,” “seeks,” “will,” “may” and similar expressions, and statements which are other than statements of historical facts, are “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties, which could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. The Company’s expectations, beliefs and projections contained herein are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that such expectations, beliefs or projections will result or be achieved or accomplished. In addition to other factors, the following are important factors that could cause actual results to differ materially from those discussed in the forward-looking statements: the Company being unable to achieve the anticipated strategic, financial and other benefits of the acquisition; the impact of future significant transactions, if any, including the potential separation of the Company into two companies; changes in laws, regulations or judicial interpretations to which the Company is subject, including those involving derivatives, taxes, safety, employment, climate change, other environmental matters, real property, and exploration and production activities such as hydraulic fracturing; governmental/regulatory actions, initiatives and proceedings, including those involving rate cases (which address, among other things, target rates of return, rate design, retained natural gas and system modernization), environmental/safety requirements, affiliate relationships, industry structure, and franchise renewal; changes in economic conditions, including the imposition of additional tariffs on U.S. imports and related retaliatory tariffs, inflationary pressures, supply chain issues, liquidity challenges, and global, national or regional recessions, and their effect on the demand for, and customers’ ability to pay for, the Company’s products and services; the Company’s ability to complete strategic transactions and to recognize the anticipated benefits of such transactions; governmental/regulatory actions and/or market pressures to reduce or eliminate reliance on natural gas; changes in the price of natural gas; financial and economic conditions, including the availability of credit, and occurrences affecting the Company’s ability to obtain financing on acceptable terms for working capital, capital expenditures, other investments, and acquisitions, including any downgrades in the Company’s credit ratings and changes in interest rates and other capital market conditions; the impact of information technology disruptions, cybersecurity or data security breaches, including the impact of issues that may arise from the use of artificial intelligence technologies; factors affecting the Company’s ability to successfully identify, drill for and produce economically viable natural gas reserves, including among others geology, lease availability and costs, title disputes, weather conditions, water availability and disposal or recycling opportunities of used water, shortages, delays or unavailability of equipment and services required in drilling operations, insufficient gathering, processing and transportation capacity, the need to obtain governmental approvals and permits, and compliance with environmental laws and regulations; increased costs or delays or changes in plans with respect to Company projects or related projects of other companies, as well as difficulties or delays in obtaining necessary governmental approvals, permits or orders or in obtaining the cooperation of interconnecting facility operators; the cost and effects of legal and administrative claims against the Company or activist shareholder campaigns to effect changes at the Company; uncertainty of natural gas reserve estimates; significant differences between the Company’s projected and actual production levels for natural gas; changes in demographic patterns and weather conditions (including those related to climate change); or economic disruptions or uninsured losses resulting from major accidents, fires, severe weather, natural disasters, terrorist activities or acts of war, as well as economic and operational disruptions due to third-party outages. The Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date thereof.

Media Contact: Karen Merkel | 716-857-7654
Analyst Contact: Ryan Vossler | 716-857-7158

– New Phase 1 data highlight flexibility of injection site for ribupatide injection

– Four additional oral presentations from Hengrui Pharma add to the clinical evidence behind Kailera’s pipeline

WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) — Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced Phase 1 data for ribupatide injection, a GLP-1/GIP receptor dual agonist currently advancing through global Phase 3 clinical trials, presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, partner Hengrui Pharma delivered four oral presentations highlighting clinical data from programs now in global development by Kailera, including ribupatide injection, oral small molecule GLP-1 receptor agonist safiglipron, also known as KAI-7535 (HRS-7535), and injectable GLP-1/GIP/glucagon receptor tri-agonist KAI-4729 (HRS-4729).

EASD 2026 Presentations

Ribupatide Phase 1 Injection Site Clinical Trial

Kailera’s Phase 1 single-dose, crossover trial investigated the effect of injection site on the relative bioavailability and safety of ribupatide injection administered subcutaneously in adults living with obesity or overweight. The trial enrolled 51 participants and consisted of three treatment periods, each with a different injection site (abdomen, upper arm, thigh) administered according to a randomized sequence (n=17 per sequence). Participants received a single 2 mg dose of ribupatide injection on Day 1 of each 29-day period. Plasma drug exposure following subcutaneous ribupatide injection to the upper arm or thigh was similar to that observed following abdominal injection, supporting these sites as alternative injection locations. Ribupatide injection was generally well tolerated irrespective of injection site, with no new safety signals identified; most treatment-emergent adverse events (TEAEs) were mild and gastrointestinal in nature.

Additional Presentations at EASD 2026

Among four additional presentations on GLP-1 therapeutics from partner Hengrui Pharma, new Phase 1 findings for HRS-4729 (KAI-4729) provided an early look at the clinical profile of the investigational GLP-1/GIP/glucagon receptor tri-agonist in obesity.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of HRS-4729, a novel GLP-1/GIP/glucagon triple-receptor agonist: a randomized, double-blind, placebo-controlled Phase 1 study

The randomized, double-blind, placebo-controlled first-in-human trial evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of HRS-4729 (KAI-4729) injection in adult participants with a baseline BMI ranging from 19 kg/m2 to 35 kg/m2 in the SAD portion and from 28 kg/m2 to 40 kg/m2 in the MAD portion. Participants received once-weekly doses of 1 mg, 4 mg, 8 mg or 12 mg HRS-4729, 4 mg ribupatide (active control) or placebo for 12 weeks. In the MAD portion of the trial at Week 12, participants receiving multiple doses of 12 mg of HRS-4729 (N=10) achieved a mean weight loss of up to 16.0% from baseline and 67.3% mean reduction in liver fat content. Ribupatide (4 mg) (N=10) demonstrated a mean reduction in body weight of 16.7% and 38.4% mean reduction in liver fat content. HRS-4729 and ribupatide injection demonstrated favorable safety and tolerability data consistent with GLP-1-based treatments. Most treatment-emergent adverse events (TEAEs) were mild to moderate and gastrointestinal-related.

Kailera plans to initiate a Phase 1 clinical trial of KAI-4729 outside of China in 2026, with data expected in 2027.

Other presentations by Hengrui Pharma include:

All presentations will be accessible on the Scientific Publications section of the Kailera website following the congress. Additional information can be found on the EASD website.

References:

  1. Marianne Camargo, MD. (2026, October 1). Effect of injection site on the relative bioavailability and safety of ribupatide, a novel dual GLP-1/GIP receptor agonist: Phase 1, randomized, single-dose crossover study result. Annual Meeting of the European Association for the Study of Diabetes (EASD), October 2026.
  2. Wen Q, He K, Li C, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of HRS-4729, a novel GLP-1/GIP/glucagon triple-receptor agonist: a randomized, double-blind, placebo-controlled Phase 1 study. Late-Breaking Abstract LBA 41. EASD 62nd Annual Meeting, Milan, 2026.

About Ribupatide

Ribupatide is a GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide) receptor dual agonist peptide being developed as a once-weekly subcutaneous injection and as a once-daily oral pill for the treatment of obesity and overweight. Once-weekly ribupatide injection has been studied in more than 3,000 clinical trial participants who have been dosed with treatment out to 52 weeks, including in multiple late-stage clinical trials conducted by Hengrui in China. Hengrui submitted an NDA to the National Medical Products Administration (NMPA) in China for long-term weight management in adults. In May 2024, Hengrui granted Kailera exclusive global rights outside Greater China to develop, manufacture and commercialize its portfolio of innovative GLP-1 therapeutics, including ribupatide injection and ribupatide oral. Kailera is currently evaluating ribupatide injection for the treatment of obesity in the KaiNETIC global Phase 3 clinical program. Based on compelling clinical data to date, Hengrui is advancing once-daily ribupatide oral to Phase 3 clinical trials in China, and Kailera plans to initiate Phase 3 global trials in the first half of 2027.

About Kailera Therapeutics

Kailera Therapeutics (Kailera) is a clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. With an obesity-first focus, Kailera is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate, ribupatide injection (also known as KAI-9531), that has the potential for the greatest weight loss. Ribupatide injection is in global Phase 3 trials as a once-weekly injectable GLP-1/GIP receptor dual agonist. Kailera is expanding the ribupatide franchise by developing a once-daily oral formulation with the goal of providing an oral option with the potential for compelling weight loss and highly differentiated tolerability. Additionally, Kailera is advancing the development of safiglipron (also known as KAI-7535), a once-daily oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera’s vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. Kailera is based in Waltham, MA. For more information, visit www.kailera.com and follow us on LinkedIn and X.

Special Note Regarding Kailera Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the profile of product candidates, the potential of Kailera’s portfolio, the timing, design and outcome of research and development activities, including with respect to the timing of initiation and completion of clinical trials and the design and goals of clinical trials, market opportunities for product candidates, and the competitive landscape, and the availability of publications. Forward-looking statements can be identified by terms such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “suggest,” “plan,” “goal,” “vision,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or similar expressions and the negatives of those terms. Kailera cannot assure you that the forward-looking statements in this press release will prove to be accurate. Information in this press release may also include statements relating to past performance, which should not be regarded as a reliable indicator of future performance. Forward-looking statements are based on current expectations and assumptions together with projections of the future which are inherently uncertain, and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, uncertainties inherent in clinical development, regulatory review, manufacturing, competition, market opportunities, reliance on third parties, estimates of capital requirements, needs for additional financing, and other important factors, including those discussed under the caption “Risk Factors” in Kailera’s filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release, and Kailera undertakes no obligation to update or revise any forward-looking statements. Kailera may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on these forward-looking statements.

Contact Information

Maura Gavaghan
Vice President, Investor Relations
maura.gavaghan@kailera.com

Anna Robinson
Vice President, Communications
anna.robinson@kailera.com

DAYTONA BEACH, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) — Brown & Brown, Inc. (NYSE: BRO) announces it will release its 2026 third-quarter earnings on Monday, October 26, 2026, after the close of the market. On Tuesday, October 27, 2026, J. Powell Brown, Brown & Brown’s president and chief executive officer, and R. Andrew Watts, Brown & Brown’s executive vice president and chief financial officer, will host an investor update conference call concerning Brown & Brown’s third-quarter 2026 financial results. You are invited to listen to the call, which will be broadcast live on Brown & Brown’s website at 8:00 a.m. EDT. Simply log on to www.bbrown.com and click on “Investor Relations” and then “Calendar of Events.”

If you are unable to listen during the live webcast, audio from the conference call will be archived on Brown & Brown’s website, www.bbrown.com, for 14 days after the live broadcast. To access the website replay, go to “Investor Relations” and click on “Calendar of Events.”

About Brown & Brown, Inc.

Brown & Brown, Inc. (NYSE: BRO) is a leading insurance brokerage firm delivering comprehensive and customized insurance solutions and specialization since 1939. With a global presence spanning 700+ locations and a team of approximately 23,000 professionals, we are dedicated to delivering scalable, innovative strategies for our customers at every step of their growth journey. Learn more at BBrown.com.

This press release may contain certain statements relating to future results, which are forward-looking statements, including those associated with the timing of the release of our third-quarter results. These statements are not historical facts but instead represent only the current belief of Brown & Brown, Inc. and its subsidiaries (collectively the “Company”) regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that actual events may differ from anticipated events contemplated by these forward-looking statements and that we may release our third-quarter results at a later date as a result. Further information concerning the Company and its business, including factors that potentially could materially affect the Company’s release of its financial results, is contained in the Company’s filings with the Securities and Exchange Commission. All forward-looking statements made herein are made only as of the date of this release, and the Company does not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which the Company hereafter becomes aware.

For more information:

R. Andrew Watts
Chief Financial Officer
(386) 239-5770

Novo reports analysis from STEP UP trial sub-population in which most participants with elevated liver fat achieved improved liver health after 72 weeks of Wegovy® (injectable semaglutide 7.2 and 2.4 mg) treatment.

  • 9 in 10 achieved normal liver fat levels: Among participants with liver fat above 5%, 88.5% in the pooled group of people taking Wegovy® (injectable semaglutide 7.2 and 2.4 mg) achieved normal liver fat levels below 5% by week 72
  • Liver fat was reduced by nearly two-thirds: Measures showed liver fat declined from 8.8% to 3.1% at week 72 with Wegovy®
  • Wegovy® showed benefits in liver despite low baseline disease burden: Even participants with low baseline liver fat saw improvements in liver health with Wegovy® treatment

Bagsværd, Denmark, 1 October 2026 – Novo Nordisk today presented post hoc analysis of data from a STEP UP trial sub-population with 55 participants, showing that Wegovy® (pooled semaglutide 7.2 and 2.4 mg) reduced liver fat in adults with obesity without diabetes.1 Change in percentage of liver fat, determined by magnetic resonance imaging (MRI), showed that mean liver fat in the group taking semaglutide declined from 8.8% at baseline to 3.1% at week 72. In addition, the analysis showed that 26 participants entered the trials with liver fat above 5% and 88.5% of them – 23 participants – reached the below-5% threshold by week 72, bringing their liver fat to normal levels. The findings are presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan, Italy.1

“This analysis showed that semaglutide reduced liver fat and was linked to better overall liver health in adults with obesity,” said Eric Lawitz, MD, Texas Liver Institute and University of Texas Health San Antonio. “These findings suggest semaglutide may help address liver disease early – before it becomes a serious health problem – that could harm the heart, kidney, liver and metabolic health in the long term. This is important because as many as three in four people with obesity may have excess liver fat.“

What was the STEP UP pooled analysis of liver health?
The post hoc explorative analysis pooled 1,919 adults across STEP UP and STEP UP T2D, of whom 1,312 received semaglutide 7.2 mg, 304 received semaglutide 2.4 mg, and 303 received placebo.2,3 At baseline, more than 94% of participants across all groups were classified as high risk for fatty liver by the Fatty Liver Index (FLI), while fewer than 1% met criteria for advanced fibrosis risk by the FIB-4 index. The population was therefore representative of individuals with obesity with high risk of metabolic dysfunction-associated steatohepatitis (MASH), but with low baseline burden of advanced liver disease.1

A direct quantification of liver fat in the 55 participants with excess liver fat was determined by the non-invasive magnetic resonance imaging–proton density fat fraction (MRI-PDFF), which is the gold-standard imaging technique for quantifying hepatic steatosis.1

“These findings help us look beyond the number on the scale and better understand the quality of the weight loss seen with semaglutide”, said Filip Knop, senior vice president and chief medical officer at Novo. “Our dedicated ESSENCE MASH trial demonstrated reversal of damage in the liver in people with MASH on semaglutide treatment, and this analysis from our STEP UP obesity trial reinforces semaglutide’s beneficial impact on liver health in people with obesity.”

Novo is investigating semaglutide 2.4 mg in MASH, and today it is approved for the treatment of MASH, under the brand name Wegovy®, in the United States, Canada, the United Kingdom, China and several other markets. Semaglutide 7.2 mg is not being investigated for the treatment of MASH.

About the STEP UP trial programme
STEP UP and STEP UP T2D were phase 3b randomised, double-blind, placebo-controlled trials evaluating semaglutide 7.2 mg once weekly versus semaglutide 2.4 mg and placebo for weight management.2,3 STEP UP enrolled adults with obesity (BMI ≥30 kg/m²) without diabetes; STEP UP T2D enrolled adults with obesity and type 2 diabetes. The primary endpoints were change in body weight and proportion of participants achieving ≥5% weight loss at week 72.2,3 The pooled analysis presented at EASD 2026 is a post hoc, exploratory analysis of liver-related indices and metabolic measures and was not a pre-specified primary or secondary endpoint of the parent trials.

About ESSENCE
ESSENCE is an ongoing phase 3 trial evaluating the effect of once-weekly injectable semaglutide 2.4 mg in people with MASH and moderate to advanced liver fibrosis (stage F2 or F3).   
The trial randomised 1,197 participants 2:1 to receive semaglutide 2.4 mg or placebo, on top of standard of care, for a total of 240 weeks.4 In part 1, the objective was to demonstrate that treatment with semaglutide 2.4 mg improved liver histology at 72 weeks based on biopsy sampling from the first 800 randomised patients. Semaglutide 2.4 mg led to superior improvement in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis (removing fat, inflammation in liver cells and improving structural integrity of liver cells) with no worsening of liver fibrosis compared to placebo.4 Results from part 2 are expected in 2029. 

About semaglutide
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the effects of the naturally occurring hormone GLP-1, which regulates blood sugar and body weight. Semaglutide has been tested in several robust clinical development programmes and outcome studies in cardiometabolic diseases, including type 2 diabetes, obesity, cardiovascular disease, heart failure, chronic kidney disease, liver disease, and other related cardiometabolic diseases. Semaglutide is marketed under the brand names Wegovy® (injection or tablet), Ozempic® (injection or tablet), and Rybelsus® (tablet).

About MASLD and MASH
Metabolically-dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is characterised by excess fat accumulation in the liver and is strongly linked to obesity and type 2 diabetes. Left unaddressed, MASLD can progress to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, and cirrhosis.5 The Fatty Liver Index (FLI) is a validated non-invasive composite score using BMI, waist circumference, triglycerides, and gamma-glutamyl transferase (GGT) to estimate the risk of hepatic steatosis: values below 30 indicate “no fatty liver,” and values above 60 indicate “high risk.”6

Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube.

Contacts for further information

Novo Media:  
Ambre James-Brown
+45 3079 9289
globalmedia@novonordisk.com
Liz Skrbkova (US)
+1 609 917 0632
USMediaRelations@novonordisk.com
Novo Investors:  
Michael Novod
+45 3075 6050
nvno@novonordisk.com
Sina Meyer
+45 3079 6656
azey@novonordisk.com
Christoffer Togo Solgaard-Tullin
+45 3079 1471
cftu@novonordisk.com
Max Ung 
+45 3077 6414 
mxun@novonordisk.com 
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com
Mads Berner Bruun
+45 3075 2936
mbbz@novonordisk.com
Frederik Taylor Pitter (US)
+1 609 613 0568
fptr@novonordisk.com
Alex Bruce (US)
+1 640 230 0276
axeu@novonordisk.com

_______________________
References

  1. Lawitz E, Garvey WT, Jacobsen CSF, Quiroga M, Wilson L, Newsome PN. Effect of semaglutide on liver measures and indices: pooled analysis from the STEP UP trials. Abstract submitted to the European Association for the Study of Diabetes (EASD) Annual Meeting 2026.
  2. Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949–963. 
  3. Lingvay I, Bergenheim SJ, Buse JB, et al. STEP UP T2D trial group. Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):935–948. 
  4. Newsome PN, Sanyal AJ, Engebretsen KA, et al. Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Aliment Pharmacol Ther. 2024;60:1525–1533.
  5. Mary E Rinella, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986.
  6. A Lum Han. Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease. Diabetology & Metabolic Syndrome. 2022; 14:44.

Attachment

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.